Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 15/20 | 1.00 |
| ▸ | ABL1 | P00519 | 9/20 | 1.00 |
| ▸ | EGFR | P00533 | 4/20 | 0.78 |
| ▸ | KDR | P35968 | 4/20 | 0.78 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.78 |
| ▸ | PRKD2 | Q9BZL6 | 4/20 | 0.78 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.78 |
| ▸ | FYN | P06241 | 3/20 | 0.78 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.78 |
| ▸ | RET | P07949 | 3/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | LCK | P06239 | 2/20 | 0.78 |
| ▸ | YES1 | P07947 | 2/20 | 0.78 |
| ▸ | LYN | P07948 | 2/20 | 0.78 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.78 |
| ▸ | PRKACA | P17612 | 2/20 | 0.78 |
| ▸ | FRK | P42685 | 2/20 | 0.78 |
| ▸ | HTT | P42858 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3610160 | 0.97 | SRC (0.95) | SRCABL1EGFRKDRPRKD3 | |
| SCHEMBL14617301 | 0.93 | SRC (0.89) | SRCABL1EGFRKDRPRKD3 | |
| SCHEMBL3617461 | 0.89 | SRC (0.79) | SRCABL1EGFRKDRPRKD3 | |
| SCHEMBL409444 | 0.89 | SRC (0.82) | SRCABL1EGFRKDRPRKD3 | |
| SCHEMBL29432587 | 0.87 | SRC (1.00) | SRCABL1EGFRKDRPRKD3 | |
| SCHEMBL407934 | 0.87 | SRC (1.00) | SRCABL1EGFRKDRPRKD3 | |
| SCHEMBL409036 | 0.87 | SRC (0.80) | SRCABL1EGFRKDRPRKD3 | |
| SCHEMBL1962682 | 0.86 | SRC (0.78) | SRCABL1EGFRKDRPRKD3 | |
| SCHEMBL29355398 | 0.86 | SRC (1.00) | SRCABL1EGFRKDRPRKD3 | |
| SCHEMBL375322 | 0.86 | SRC (1.00) | SRCABL1EGFRKDRPRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247972-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2022-02-15 | — | — | US | disclosed |
| US-11247972-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2022-02-15 | — | — | US | disclosed |
| US-20200223803-A1 | Compositions and Methods for Treating Toxoplasmosis, Cryptosporidiosis, and Other Apicomplexan Protozoan Related Diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2020-07-16 | — | — | US | disclosed |
| US-20200223803-A1 | Compositions and Methods for Treating Toxoplasmosis, Cryptosporidiosis, and Other Apicomplexan Protozoan Related Diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2020-07-16 | — | — | US | disclosed |
| US-10544104-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | University of Washington Through its Center for Co (US) | 2020-01-28 | — | — | US | disclosed |
| US-10544104-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | University of Washington Through its Center for Co (US) | 2020-01-28 | — | — | US | disclosed |
| US-20180022709-A1 | Compositions and Methods for Treating Toxoplasmosis, Cryptosporidiosis, and Other Apicomplexan Protozoan Related Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-01-25 | — | — | US | disclosed |
| US-20180022709-A1 | Compositions and Methods for Treating Toxoplasmosis, Cryptosporidiosis, and Other Apicomplexan Protozoan Related Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-01-25 | — | — | US | disclosed |
| US-20180022709-A1 | Compositions and Methods for Treating Toxoplasmosis, Cryptosporidiosis, and Other Apicomplexan Protozoan Related Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-01-25 | — | — | US | disclosed |
| US-9765037-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2017-09-19 | — | — | US | disclosed |
| EP-1607481-A1 | Engineered protein kinases which can utilize modified nucleotide triphosphate substrates | PRINCETON UNIVERSITY (US) | 2005-12-21 | — | — | EP | disclosed |
| EP-1017823-B1 | ENGINEERED PROTEIN KINASES WHICH CAN UTILIZE MODIFIED NUCLEOTIDE TRIPHOSPHATE SUBSTRATES | UNIV PRINCETON (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1140938-B1 | HIGH AFFINITY INHIBITORS FOR TARGET VALIDATION AND USES THEREOF | UNIV PRINCETON (US) | 2003-08-27 | — | — | EP | disclosed |
| EP-1321467-A2 | High affinity inhibitors for target validation and uses thereof | Princeton University (US) | 2003-06-25 | — | — | EP | disclosed |
| US-20030073218-A1 | High affinity inhibitors for target validation and uses thereof | PRINCETON UNIVERSITY | 2003-04-17 | — | — | US | disclosed |
| US-6521417-B1 | Incubating permeabilized cells expressing mutant kinase with radiolabeled analog; cytolysis, separation by sodium dodecyl sulfate polyacrylamide gel electrophoresis | PRINCETON UNIVERSITY | 2003-02-18 | — | — | US | disclosed |
| US-20020146797-A1 | Engineered protein kinases which can utilize modified nucleotide triphosphate substrates | PRINCETON UNIVERSITY. | 2002-10-10 | — | — | US | disclosed |
| US-6390821-B1 | PHOSPHORYLATION | PRINCETON UNIVERSITY | 2002-05-21 | — | — | US | disclosed |
| US-6383790-B1 | PYRAZOLO(3,4-D)PYRIMIDINE BASED COMPOUND; ANTICARCINOGENIC AGENTS; ANTITUMOR AGENTS | PRINCETON UNIVERSITY | 2002-05-07 | — | — | US | disclosed |
| US-20020016976-A1 | Engineered protein kinases which can utilize modified nucleotide triphosphate substrates | PRINCETON UNIVERSITY | 2002-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247972-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | PNCK, TXK, CILK1 | SRC 132/4885ABL1 1181/4885EGFR 4742/4885 |
| US-10544104-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | PNCK, TXK, CILK1 | SRC 132/4885ABL1 1181/4885EGFR 4742/4885 |
| US-20180022709-A1 | Compositions and Methods for Treating Toxoplasmosis, Cryptosporidiosis, and Other Apicomplexan Protozoan Related Diseases | PNCK, TXK, CILK1 | SRC 132/4885ABL1 1181/4885EGFR 4742/4885 |
| US-20030073218-A1 | High affinity inhibitors for target validation and uses thereof | SRC, MARCKS, TEC | SRC 1/4885ABL1 18/4885EGFR 113/4885 |
| US-20200223803-A1 | Compositions and Methods for Treating Toxoplasmosis, Cryptosporidiosis, and Other Apicomplexan Protozoan Related Diseases | PNCK, TXK, CILK1 | SRC 132/4885ABL1 1181/4885EGFR 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.